Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 13/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995456 | 0.87 | LRRK2 (0.41) | HRH3 | |
| SCHEMBL1995051 | 0.83 | ADORA2A (0.39) | WDR5HRH3CHKAPDCD1CD274 | |
| SCHEMBL1998644 | 0.83 | METAP2 (0.43) | HRH3PDCD1CD274 | |
| SCHEMBL1997243 | 0.77 | HRH3 (0.44) | HRH3 | |
| SCHEMBL1998519 | 0.77 | CYP2A13 (0.42) | HRH3 | |
| SCHEMBL839667 | 0.77 | CXCR4 (0.44) | HRH3 | |
| SCHEMBL1997193 | 0.75 | HRH3 (0.46) | HRH3CHKA | |
| SCHEMBL2001890 | 0.75 | KMT2A (0.37) | HRH3 | |
| SCHEMBL1998795 | 0.75 | CYP2D6 (0.49) | HRH3 | |
| SCHEMBL2001267 | 0.74 | CHKA (0.41) | HRH3CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | claimed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | claimed |
| EP-2373627-A1 | 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063721-A1 | 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | OPRM1, OR10J3, OPRD1 | WDR5 894/4885HRH3 32/4885PDE4B 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.